Nyxoah SA (NYXH) Reports 74.3% AHI Median Reduction; Files FDA PMA Supplement
Nyxoah SA reported 12-month ACCCESS data showing a 74.3% median AHI reduction with Genio in CCC OSA patients. The company filed a PMA supplement with the FDA to expand Genio’s indication to CCC patients, with no serious adverse events reported. According to Nyxoah, a positive FDA decision could be a significant commercial catalyst.
How this was made
The 30-second read
Why it matters
If the FDA responds favorably to the PMA supplement and reimbursement becomes clearer, Genio’s commercial footprint could expand beyond the originally approved patient population.
Market read
Traders get a concrete clinical efficacy datapoint plus a regulatory filing step that can shift probability-weighted outcomes for label expansion.
What to watch
Key missing details are FDA review timeline, whether the supplement is accepted without further studies, and any reimbursement or payer coverage updates for CCC patients.
Background
The piece frames this as a mid-cycle clinical-to-regulatory update building on prior U.S. approval for Genio and topline ACCCESS data.
Ticker impact
Nyxoah reports 12-month ACCCESS data with a 74.3% median AHI reduction and files an FDA PMA supplement to expand Genio to CCC patients.
Likely upward bias as traders price in higher probability of expanded indication and future reimbursement clarity.
The article discloses new 12-month ACCCESS data plus a fresh FDA PMA supplement filing, both of which can move biotech risk perception and valuation expectations.
Market effects
Supports sentiment for sleep-disordered breathing device makers by reinforcing the FDA pathway for expanded indications.
Limited, primarily affects US-listed biotech/device sentiment rather than broad regional flows.
Low, as the catalyst is company-specific FDA regulatory progress.
Counterpoint
A PMA supplement filing does not guarantee FDA acceptance or approval timing, so near-term upside may fade if FDA requests additional data.
Key entities
- companyNyxoah SA
Medical device company reporting ACCCESS 12-month data and filing an FDA PMA supplement to expand Genio’s indication.
- productGenio
Nyxoah’s device whose indication is proposed to expand to CCC OSA patients via the PMA supplement.
- regulatorFDA
Regulatory body reviewing the PMA supplement for expanded Genio indication.